TBK1 inhibitor amlexanox exerts anti-cancer effects against endometrial cancer by regulating AKT/NF-κB signaling
International Journal of Biological Sciences · 01.01.2025 · 21 (1) · 143-159
DOI: 10.7150/ijbs.100212 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, erschienen am 01.01.2025. Verfasst von Jiha Shin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, Konyang University College of Medicine, Daejeon 35365, Republic of Korea. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Protein Serine-Threonine Kinases, NF-kappa B, Signal Transduction. Die Arbeit wurde bisher 15-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Endometrial cancer, a common gynecological malignancy, poses significant clinical challenges, particularly in advanced or recurrent cases. TANK-binding kinase 1 (TBK1), a serine/threonine kinase, plays crucial roles in inflammation and immunity by activating nuclear factor (NF)-κB and interferon regulatory factor 3. However, its specific roles in endometrial cancer remain unknown. In this study, we aimed to investigate the anti-cancer effects and underlying mechanisms of amlexanox, a TBK1 inhibitor, against endometrial cancer. The main genetic mutations in TBK1 were found to be mRNA downregulation and missense mutations. Kaplan-Meier plotter analysis revealed that low TBK1 expression was associated with a good prognosis in patients with uterine corpus endometrial carcinoma (UCEC). In vitro experiments demonstrated that TBK1 knockdown or amlexanox significantly inhibited the proliferation, cell cycle progression, and migration of endometrial cancer cells. Furthermore, the inhibitory effects of targeting TBK1 on cancer cell proliferation and migration were mediated by the protein kinase B (AKT)/NF-κB signaling pathway. Xenograft experiments revealed that both amlexanox treatment and TBK1 knockdown effectively suppressed the tumor growth. Overall, this study highlights the potent anti-cancer effects of amlexanox against endometrial cancer by modulating AKT/NF-κB signaling, thus providing a new avenue for the development of novel TBK1-targeting therapeutic strategies for UCEC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology, Konyang University College of Medicine, Daejeon 35365, Republic of Korea.
- Department of Surgery, Konyang University Hospital, Daejeon 35365, Republic of Korea.
- Myunggok Medical Research Institute, Konyang University College of Medicine, Daejeon 35365, Republic of Korea.
- Department of Anatomy, Konyang University College of Medicine, Daejeon 35365, Republic of Korea.
- Department of Pharmacology, Konyang University College of Medicine, Daejeon 35365, Republic of Korea.
- Department of Obstetrics and Gynecology, Konyang University Hospital, Daejeon, Republic of Korea.
Zitieren
APA
Shin, J., Lim, J., Han, D., Lee, S., Sung, N. S., Kim, J. S., Kim, D. K., Lee, H. Y., Lee, S. K., Shin, J., Kim, J. S., & Park, H. W. (2025). TBK1 inhibitor amlexanox exerts anti-cancer effects against endometrial cancer by regulating AKT/NF-κB signaling. International Journal of Biological Sciences, 21(1), 143-159. https://doi.org/10.7150/ijbs.100212
Vancouver
Shin J, Lim J, Han D, Lee S, Sung NS, Kim JS, et al. TBK1 inhibitor amlexanox exerts anti-cancer effects against endometrial cancer by regulating AKT/NF-κB signaling. International Journal of Biological Sciences. 2025;21(1):143-159. doi:10.7150/ijbs.100212
BibTeX
@article{Shin2025,
author = {Shin, Jiha and Lim, Jihoon and Han, Daewon and Lee, Solji and Sung, Nak Song and Kim, Jong-Seok and Kim, Do Kyung and Lee, Hoi Young and Lee, Sung Ki and Shin, Jongdae and Kim, Jeong Sig and Park, Hwan-Woo},
title = {TBK1 inhibitor amlexanox exerts anti-cancer effects against endometrial cancer by regulating AKT/NF-κB signaling},
journal = {International Journal of Biological Sciences},
year = {2025},
volume = {21},
number = {1},
pages = {143--159},
doi = {10.7150/ijbs.100212}
}
EUVIMED